<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="198">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 16, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02247349</url>
  </required_header>
  <id_info>
    <org_study_id>CA001-030</org_study_id>
    <secondary_id>2014-002372-89</secondary_id>
    <nct_id>NCT02247349</nct_id>
  </id_info>
  <brief_title>BMS-986012 in Relapsed/Refractory SCLC</brief_title>
  <official_title>A Phase 1/2 Multicenter Study of BMS-986012 in Subjects With Relapsed/Refractory Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Belgium: The Federal Public Service (FPS) Health, Food Chain Safety and Environment</authority>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <authority>South Korea: Korea Food and Drug Administration (KFDA)</authority>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <authority>Canada: Health Canada</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety, tolerability, pharmacokinetics,
      immunogenicity, antitumor activity and pharmacodynamics of BMS-986012 in subjects with
      relapsed/refractory SCLC.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety as measured by frequency of worst grade of adverse events (AEs), worst grade of serious adverse events (SAEs), incidence of adverse events leading to discontinuations, and deaths</measure>
    <time_frame>Weekly for 1st and 2nd 21-day cycles, then once every 3 weeks during study treatment, at end of treatment and every 30 days during clinical follow-up until resolution of adverse events or 100 days after the last dose of study medication (Approx 3 years)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety as measured by frequency of worst grade of adverse events (AEs), worst grade of serious adverse events (SAEs), incidence of adverse events leading to discontinuations, and deaths graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), as appropriate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed serum concentration (Cmax) for BMS-986012 (anti-fucosyl-GM1)</measure>
    <time_frame>At multiple timepoints during first 4 cycles then every 4th cycle, at end of treatment and during clinical follow-up (Approx duration of study 3 years)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed serum concentration (Tmax) for BMS-986012 (anti-fucosyl-GM1)</measure>
    <time_frame>At multiple timepoints during first 4 cycles then every 4th cycle, at end of treatment and during clinical follow-up (Approx duration of study 3 years)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed serum concentration at the end of a dosing interval (Ctau) for BMS-986012 (anti-fucosyl-GM1)</measure>
    <time_frame>At multiple timepoints during first 4 cycles then every 4th cycle, at end of treatment and during clinical follow-up (Approx duration of study 3 years)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time curve from time zero to time t (AUC(0-t)) for BMS-986012 (anti-fucosyl-GM1)</measure>
    <time_frame>At multiple timepoints during first 4 cycles then every 4th cycle, at end of treatment and during clinical follow-up (Approx duration of study 3 years)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time curve in one dosing interval (AUC(TAU)) for BMS-986012 (anti-fucosyl-GM1)</measure>
    <time_frame>At multiple timepoints during first 4 cycles then every 4th cycle, at end of treatment and during clinical follow-up (Approx duration of study 3 years)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall response (BOR) for BMS-986012 (anti-fucosyl-GM1)</measure>
    <time_frame>Approximately every 6 weeks until disease progression or every 3-4 months for subjects with a confirmed response (Approx duration of study 3 years)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Best overall response (BOR): defined as the best response designation over the study as a whole, recorded between the dates of first dose until the last tumor assessment prior to subsequent therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) for BMS-986012 (anti-fucosyl-GM1)</measure>
    <time_frame>Approximately every 6 weeks until disease progression or every 3-4 months for subjects with a confirmed response (Approx duration of study 3 years)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Objective Response Rate (ORR): defined as the total number of subjects whose best overall response (BOR) is either a complete response (CR) or partial response (PR) divided by the total number of subjects in the population of interest</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response for BMS-986012 (anti-fucosyl-GM1)</measure>
    <time_frame>Approximately every 6 weeks until disease progression or every 3-4 months for subjects with a confirmed response (Approx duration of study 3 years)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Duration of Response: defined as the time between the date of first response and the subsequent date of objectively documented disease progression or death, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) for BMS-986012 (anti-fucosyl-GM1)</measure>
    <time_frame>Approximately every 6 weeks until disease progression or every 3-4 months for subjects with a confirmed response (Approx duration of study 3 years)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Progression Free Survival (PFS): defined as the time from the first dose of study medication to the date of the first objective documentation of tumor progression or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival Rate (PFSR) at week &quot;t&quot;; for BMS-986012 (anti-fucosyl-GM1)</measure>
    <time_frame>Approximately every 6 weeks until disease progression or every 3-4 months for subjects with a confirmed response (Approx duration of study 3 years)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Progression Free Survival Rate (PFSR) at week &quot;t&quot;: defined as the proportion of subjects who remain progression free and surviving at &quot;t&quot; weeks (t=12, 24, 36, etc)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) for BMS-986012 (anti-fucosyl-GM1)</measure>
    <time_frame>Approximately every 6 weeks until disease progression or every 3-4 months for subjects with a confirmed response (Approx duration of study 3 years)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Overall Survival (OS): defined as the time between the date of first dose of study medication and the date of death. For subjects without documentation of death, OS will be censored on the last date the subject was known to be alive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Rate (OSR) at month &quot;t&quot; for BMS-986012 (anti-fucosyl-GM1)</measure>
    <time_frame>Approximately every 6 weeks until disease progression or every 3-4 months for subjects with a confirmed response (Approx duration of study 3 years)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Overall Survival Rate (OSR) at month &quot;t&quot;: defined as the proportion of subjects surviving at &quot;t&quot; months (eg, t=6, 12, 24 months, etc)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of specific anti-drug antibodies (ADA) to BMS-986012 every 3 weeks for first 3 cycles then every 4 cycles, at end of treatment and during clinical follow-up</measure>
    <time_frame>Every 3 weeks for first 3 cycles then every 4 cycles, at end of treatment and during clinical follow-up (Approx duration of study 3 years)</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the QTcF following administration of BMS-986012 at multiple timepoints during first cycle, then Day 1 of subsequent cycles and at end of treatment</measure>
    <time_frame>At multiple timepoints during first cycle, then Day 1 of subsequent cycles and at end of treatment (Approx duration of study 3 years)</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">136</enrollment>
  <condition>Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Dose Escalation Dose -1: BMS-986012 (anti-fucosyl-GM1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation Dose 1: BMS-986012 (anti-fucosyl-GM1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation Dose 2: BMS-986012 (anti-fucosyl-GM1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation Dose 3: BMS-986012 (anti-fucosyl-GM1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation Dose 4: BMS-986012 (anti-fucosyl-GM1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Cohort A: BMS-986012 (anti-fucosyl-GM1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Cohort B: BMS-986012 (anti-fucosyl-GM1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Cohort C: BMS-986012 (anti-fucosyl-GM1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Cohort D: BMS-986012 (anti-fucosyl-GM1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BMS-986012 (anti-fucosyl-GM1)</intervention_name>
    <arm_group_label>Dose Escalation Dose -1: BMS-986012 (anti-fucosyl-GM1)</arm_group_label>
    <arm_group_label>Dose Escalation Dose 1: BMS-986012 (anti-fucosyl-GM1)</arm_group_label>
    <arm_group_label>Dose Escalation Dose 2: BMS-986012 (anti-fucosyl-GM1)</arm_group_label>
    <arm_group_label>Dose Escalation Dose 3: BMS-986012 (anti-fucosyl-GM1)</arm_group_label>
    <arm_group_label>Dose Escalation Dose 4: BMS-986012 (anti-fucosyl-GM1)</arm_group_label>
    <arm_group_label>Dose Expansion Cohort A: BMS-986012 (anti-fucosyl-GM1)</arm_group_label>
    <arm_group_label>Dose Expansion Cohort B: BMS-986012 (anti-fucosyl-GM1)</arm_group_label>
    <arm_group_label>Dose Expansion Cohort C: BMS-986012 (anti-fucosyl-GM1)</arm_group_label>
    <arm_group_label>Dose Expansion Cohort D: BMS-986012 (anti-fucosyl-GM1)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Histological or cytological confirmed small cell lung cancer (SCLC)

          -  Performance Status 0-1

          -  Adequate organ function

          -  Measurable disease

        Exclusion Criteria:

          -  Known or suspected brain metastasis

          -  Small cell cancer not lung in origin

          -  Significant or acute medical illness

          -  Uncontrolled or significant cardiac disease

          -  Infection

          -  â‰¥ Grade 2 peripheral neuropathy

          -  Concomitant malignancies

          -  HIV related disease or known or suspected HIV+

          -  Hepatitis B or C infection

          -  ECG abnormalities as defined by the protocol

          -  Allergies or hypersensitivities to monoclonal antibodies, BMS-986012 or related
             compounds, including fucosyl-GM1 vaccine
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:</last_name>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT# and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neal Ready, Site 0001</last_name>
      <phone>919-681-6932</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>St. Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0020</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0011</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0002</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Gent</city>
        <zip>B-9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0015</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0012</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Quincy Chu, Site 0003</last_name>
      <phone>780-989-8157</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nova Scotia Health Authority Qeii Health Sciences Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Snow, Site 0017</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosalyn Juergens, Site 0019</last_name>
      <phone>905-387-9711</phone>
      <phone_ext>x64604</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0010</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natasha Leighl, Site 0007</last_name>
      <phone>416-946-4501</phone>
      <phone_ext>2913</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0008</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0013</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacion De Investigacion De Diego</name>
      <address>
        <city>San Juan</city>
        <zip>00927</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mirelis Acosta-Rivera, Site 0009</last_name>
      <phone>7875688045</phone>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://ctr.bms.com/ctd/start.do</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>February 2016</verification_date>
  <lastchanged_date>June 9, 2016</lastchanged_date>
  <firstreceived_date>September 19, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
